🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Manning & Napier Group’s SUPN Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+38 Shares
Current Position
38 Shares
$1,778 Value

Manning & Napier Group's SUPN Position Overview

Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 38 shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $1,778, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Manning & Napier Group has initiated a new position in SUPN, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Manning & Napier Group's Supernus Pharmaceuticals (SUPN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Supernus Pharmaceuticals (SUPN) Trades by Manning & Napier Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +38 New Buy 38 $46.79

Manning & Napier Group's Supernus Pharmaceuticals Investment FAQs

Manning & Napier Group first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q2 2026, acquiring 38 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Manning & Napier Group has held Supernus Pharmaceuticals, Inc. (SUPN) for 1 quarters since Q2 2026.

Manning & Napier Group's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q2 2026, adding 38 shares worth $1,778.

According to the latest 13F filing for Q2 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 38 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $1,778.

As of the Q2 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.

Manning & Napier Group's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 38 shares, as reported at the end of Q2 2026.